Clinical Trials Browser

Phase 3 × OTHER × Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) × Clear all

NCT05956639 2023-07-21

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

Phase 3 Recruiting

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)